Cargando…

Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein

BACKGROUND: Oncologic patients who are extreme responders to molecularly targeted therapy provide an important opportunity to better understand the biologic basis of response and, in turn, inform clinical decision making. Malignant neoplasms with an uncertain histologic and immunohistochemical chara...

Descripción completa

Detalles Bibliográficos
Autores principales:	Subbiah, Vivek, Westin, Shannon N, Wang, Kai, Araujo, Dejka, Wang, Wei-Lien, Miller, Vincent A, Ross, Jeffrey S, Stephens, Phillip J, Palmer, Gary A, Ali, Siraj M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896681/ https://www.ncbi.nlm.nih.gov/pubmed/24422672 http://dx.doi.org/10.1186/1756-8722-7-8

Ejemplares similares

Spindle cell sarcoma with KIAA1549-BRAF resembling infantile fibrosarcoma morphologically: A case report and literature review
por: Fujikawa, Tomoko, et al.
Publicado: (2022)

Incidence of kiaa1549-braf fusion gene in Egyptian pediatric low grade glioma
por: Taha, Hala, et al.
Publicado: (2015)

LGG-53. Evaluation of KIAA-BRAF1549 fusions in pilocytic astrocytoma with clinicopathological correlation
por: Dandapath, Iman, et al.
Publicado: (2022)

Detection of the KIAA1549-BRAF fusion gene in cells forming microvascular proliferations in pilocytic astrocytoma
por: Yamashita, Shinji, et al.
Publicado: (2019)

BRAF Fusion Analysis in Pilocytic Astrocytomas: KIAA1549-BRAF 15-9 Fusions Are More Frequent in the Midline Than Within the Cerebellum
por: Faulkner, Claire, et al.
Publicado: (2015)

KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas
por: Becker, Aline Paixão, et al.
Publicado: (2015)

An optimized workflow to improve reliability of detection of KIAA1549:BRAF fusions from RNA sequencing data
por: Sommerkamp, Alexander C., et al.
Publicado: (2020)

Generation of patient-derived models from a metastatic pediatric diffuse leptomeningeal glioneuronal tumor with KIAA1549::BRAF fusion
por: Messiaen, Julie, et al.
Publicado: (2022)

LGG-54. DETECTION OF THE KIAA1549-BRAF FUSION GENE IN CELLS FORMING MICROVASCULAR PROLIFERATIONS IN PILOCYTIC ASTROCYTOMA
por: Yamashita, Shinji, et al.
Publicado: (2020)

LGG-07. Novel CRISPR/Cas9 induced KIAA1549:BRAF fusion model for preclinical studies of pediatric gliomas
por: Patel, Krupesh, et al.
Publicado: (2022)

KIAA1549-BRAF Expression Establishes a Permissive Tumor Microenvironment Through NFκB-Mediated CCL2 Production
por: Chen, Ran, et al.
Publicado: (2018)

Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing
por: Selt, Florian, et al.
Publicado: (2016)

Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report
por: Chou, Yun-Tse, et al.
Publicado: (2022)

UBTOR/KIAA1024 regulates neurite outgrowth and neoplasia through mTOR signaling
por: Zhang, Hefei, et al.
Publicado: (2018)

Erratum to “KIAA1549-BRAF Expression Establishes a Permissive Tumor Microenvironment Through NFκB-Mediated CCL2 Production” [Neoplasia, Volume: 21, Issue:1, (2019) 52–60]
por: Chen, Ran, et al.
Publicado: (2020)

PAX5-KIAA1549L: a novel fusion gene in a case of pediatric B-cell precursor acute lymphoblastic leukemia
por: Anderl, Stefanie, et al.
Publicado: (2015)

Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel SNX8-BRAF Gene Fusion
por: Offer, Katharine, et al.
Publicado: (2023)

Dual inhibition of BRAF and mTOR in BRAF(V600E)-mutant pediatric, adolescent, and young adult brain tumors
por: Sen, Shiraj, et al.
Publicado: (2020)

mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms
por: Exner, Samantha, et al.
Publicado: (2021)

LGG-06. Selumetinib in pediatric patients with non-neurofibromatosis type 1-associated, non-optic pathway (OPG) and non-pilocytic recurrent/progressive low-grade glioma harboring BRAFV600E mutation or BRAF-KIAA1549 fusion: a multicenter prospective Pediatric Brain Tumor Consortium (PBTC) Phase 2 trial
por: Fangusaro, Jason, et al.
Publicado: (2022)

Development of novel DNAJB6-KIAA1522-p-mTOR three-protein prognostic prediction models for CRC
por: Jiang, Yu-Juan, et al.
Publicado: (2022)

RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
por: Poulikakos, Poulikos I., et al.
Publicado: (2010)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
por: Li, Qingfang, et al.
Publicado: (2022)

Dual Targeting of BRAF and mTOR Signaling in Melanoma Cells with Pyridinyl Imidazole Compounds
por: Palušová, Veronika, et al.
Publicado: (2020)

Interactome dynamics of RAF1-BRAF kinase monomers and dimers
por: Iglesias-Martinez, Luis F., et al.
Publicado: (2023)

Sustained Response to the Mitogen-Activated Extracellular Kinase Inhibitor Trametinib in a Spindle Cell Sarcoma Harboring a QKI-RAF1 Gene Fusion
por: Panet, François, et al.
Publicado: (2022)

GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells
por: Pópulo, Helena, et al.
Publicado: (2013)

Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors
por: Chatelle, Claire V., et al.
Publicado: (2016)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
por: Schreck, Karisa C., et al.
Publicado: (2019)

RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling
por: Yao, Zhan, et al.
Publicado: (2018)

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011)

Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations
por: Fritsche-Guenther, Raphaela, et al.
Publicado: (2018)

Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway
por: Čokić, Vladan P., et al.
Publicado: (2015)

Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations
por: Obaid, Nourah Mohammad, et al.
Publicado: (2017)

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin
por: Molhoek, Kerrington R, et al.
Publicado: (2005)

1549. Impact of New Fluoroquinolone Breakpoints on Enterobacteriaceae Susceptibility Rates and Clinical Outcomes
por: Pettit, Natasha N, et al.
Publicado: (2019)

FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors
por: Jardim, Denis L., et al.
Publicado: (2014)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib
por: Chung, Jon H., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vh1cs7s6um6an9o1iojuo762rn